Showing 1871-1880 of 2526 results for "".
- Belkin Vision’s New Glaucoma Laser Technology Now Available in Germanyhttps://modernod.com/news/belkin-visions-new-glaucoma-laser-technology-now-available-in-germany/2481425/Belkin Vision announced that its Direct SLT Eagle device, an automated, non-contact glaucoma laser treatment, is being used to treat glaucoma patients at The University Eye Clinic in Bochum, Germany. “The Eagle by Belkin Vision will be transformative for many of the esti
- Researchers Identify Potential Cause of Keratoconushttps://modernod.com/news/researchers-identify-potential-cause-of-keratoconus/2481402/Researchers at the University of North Texas Health Science Center are the first to characterize extracellular vesicles (EVs) in the tears of patients with keratoconus, according to an National Eye Institute news release. Dimitrios Karamichos, PhD, executive director of the North
- Novaliq Plans to File a Marketing Authorization Application for CyclASol in the EU for Dry Eye Diseasehttps://modernod.com/news/novaliq-plans-to-file-a-markting-authorization-application-for-cyclasol-in-the-eu-for-the-treatment-of-dry-eye-disease-in-july-2023/2481396/Novaliq announced its plans for filing a marketing authorization application (MAA) CyclASol (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED), in the European Union. The Committee for Medicinal Products for H
- RxSight Announces Pricing of Public Offering of Common Stockhttps://modernod.com/news/rxsight-announces-pricing-of-public-offering-of-common-stock/2481395/RxSight, maker of the RxSight Light Adjustable Lens system, announced it has priced its underwritten public offering. RxSight expects to sell 4 million shares of its common stock at a price to the public of $12.50 per share. RxSight has granted the underwriter a 30-day op
- Omeros Receives $200 Million Milestone Payment from Raynerhttps://modernod.com/news/omeros-receives-200-million-milestone-payment-from-rayner/2481391/Omeros announced that Rayner has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021, pursuant to which Omeros sold its ophthalmology product Omidria to Rayner in December of 2021. Omeros received
- Harrow Announces Permanent, Product-Specific J-Code for Iheezo for Ocular Surface Anesthesiahttps://modernod.com/news/harrow-announces-permanent-product-specific-j-code-j2403-for-iheezo-for-ocular-surface-anesthesia/2481378/Harrow announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent, product-specific J-code for Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Under the Healthcare Common Procedure Coding System (HCPCS), the Iheezo J‑co
- VSP Vision Names New President of VSP Ventureshttps://modernod.com/news/kathleen-steele-named-president-of-vsp-ventures/2481370/VSP Vision announced that Kathleen Steele has been named president of VSP Ventures. In the role, Ms. Steele will lead the company’s business unit that provides care-focused choices for doctors of optometry looking for practice transition options. She will report to Kate Renwick-Es
- Study: Maintaining the Enzyme ACE2 in the Gut May Prevent Diabetic Blindnesshttps://modernod.com/news/type-1-diabetes-maintaining-the-enzyme-ace2-in-the-gut-prevents-diabetic-blindness/2481360/A new study from the University of Alabama at Birmingham shows that the progressive damage to blood vessels in the light-sensitive tissue at the back of the eye may be due to a leaky small intestine that weakens the barrier between gut bacteria and the blood system. The study publi
- Study: Zebrafish Model Helps Explain Eye Developmenthttps://modernod.com/news/study-zebrafish-model-helps-explain-eye-development/2481352/Scientists at the National Eye Institute (NEI) have developed a zebrafish model of NEDBEH—a rare genetic disorder that can cause coloboma, where parts of the eye are missing due to developmental defects. The model provides a new tool for understanding the eye's embryonic developmen
- Nanotechnology May Improve Gene Therapy for Blindnesshttps://modernod.com/news/nanotechnology-may-improve-gene-therapy-for-blindness/2481350/Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness, according to the National Eye Institute. A collaborative team of researchers with Oregon Health & Science University and Oreg